Literature DB >> 33393420

Neurological and Neuropsychological Changes Associated with SARS-CoV-2 Infection: New Observations, New Mechanisms.

Muhammad Ali Haidar1, Hussam Jourdi2, Zeinab Haj Hassan3, Ohanes Ashekyan1, Manal Fardoun4, Zena Wehbe4, Dina Maaliki5, Maya Wehbe6, Stefania Mondello7, Samar Abdelhady8, Shima Shahjouei9, Maya Bizri10, Yehia Mechref11, Mark S Gold12, Ghassan Dbaibo1,13,14, Hassan Zaraket13,15, Ali H Eid5,13, Firas Kobeissy1,16.   

Abstract

SARS-CoV-2 infects cells through angiotensin-converting enzyme 2 (ACE2), a ubiquitous receptor that interacts with the virus' surface S glycoprotein. Recent reports show that the virus affects the central nervous system (CNS) with symptoms and complications that include dizziness, altered consciousness, encephalitis, and even stroke. These can immerge as indirect immune effects due to increased cytokine production or via direct viral entry into brain tissue. The latter is possible through neuronal access via the olfactory bulb, hematogenous access through immune cells or directly across the blood-brain barrier (BBB), and through the brain's circumventricular organs characterized by their extensive and highly permeable capillaries. Last, the COVID-19 pandemic increases stress, depression, and anxiety within infected individuals, those in isolation, and high-risk populations like children, the elderly, and health workers. This review surveys the recent updates of CNS manifestations post SARS-CoV-2 infection along with possible mechanisms that lead to them.

Entities:  

Keywords:  ARDS; COVID-19; SARS; angiotensin; autoantibodies; encephalitis; inflammation; neurodegeneration; pandemic; stroke; viral infection

Year:  2021        PMID: 33393420     DOI: 10.1177/1073858420984106

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  7 in total

1.  Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme.

Authors:  Anjing Chen; Wenguo Zhao; Xiaolong Li; Guangyu Sun; Zhaoyin Ma; Lingyu Peng; Zhongyang Shi; Xingang Li; Jie Yan
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

Review 2.  SARS-CoV-2 involvement in central nervous system tissue damage.

Authors:  Muhammad Ali Haidar; Zaynab Shakkour; Mohammad Amine Reslan; Nadine Al-Haj; Perla Chamoun; Karl Habashy; Hasan Kaafarani; Shima Shahjouei; Sarah H Farran; Abdullah Shaito; Esber S Saba; Bassam Badran; Mirna Sabra; Firas Kobeissy; Maya Bizri
Journal:  Neural Regen Res       Date:  2022-06       Impact factor: 5.135

3.  Repeated ethanol exposure and withdrawal alters ACE2 expression in discrete brain regions: Implications for SARS-CoV-2 infection.

Authors:  Nagalakshmi Balasubramanian; Thomas D James; Selvakumar Govindhasamy Pushpavathi; Catherine A Marcinkiewcz
Journal:  bioRxiv       Date:  2022-03-29

Review 4.  Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches.

Authors:  Mohammad Mahboubi Mehrabani; Mohammad Sobhan Karvandi; Pedram Maafi; Mohammad Doroudian
Journal:  Rev Med Virol       Date:  2022-02-09       Impact factor: 11.043

Review 5.  COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction.

Authors:  Yanting Chen; Wenren Yang; Feng Chen; Lili Cui
Journal:  J Neuroinflammation       Date:  2022-09-07       Impact factor: 9.587

6.  Long-term neurological manifestations of COVID-19: prevalence and predictive factors.

Authors:  Andrea Pilotto; Viviana Cristillo; Stefano Cotti Piccinelli; Nicola Zoppi; Giulio Bonzi; Davide Sattin; Silvia Schiavolin; Alberto Raggi; Antonio Canale; Stefano Gipponi; Ilenia Libri; Martina Frigerio; Michela Bezzi; Matilde Leonardi; Alessandro Padovani
Journal:  Neurol Sci       Date:  2021-09-15       Impact factor: 3.307

Review 7.  Is there a common pathophysiological mechanism between COVID-19 and depression?

Authors:  Luciano da Silva Lopes; Raquel Oliveira Silva; Guilherme de Sousa Lima; Arthur Caminha de Araújo Costa; Daniela França Barros; Raimundo Pereira Silva-Néto
Journal:  Acta Neurol Belg       Date:  2021-07-29       Impact factor: 2.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.